Changes in Blood Components in Patients with Ovarian Cancer
Overview
Tab Title Description
Study type
ObservationalDescribes the nature of a clinical study. Types include:
- Observational study — observes people and measures outcomes without affecting results.
- Interventional study (clinical trial) — studies new tests, treatments, drugs, surgical procedures or devices.
- Medical records research — uses historical information collected from medical records of large groups of people to study how diseases progress and which treatments and surgeries work best.
Study IDs
Site IRB
- Rochester, Minnesota: 12-005263
Sponsor Protocol Number: 12-005263
About this study
The purpose of this study is to assemble a collection of serial plasma biospecimens from women with ovarian, primary peritoneal, or fallopian tube cancer for future research projects to identify changes in levels of various plasma components that occur during the course of ovarian cancer, including changes that occur with debulking surgery, chemotherapy, disease relapse, and subsequent therapy.
Participation eligibility
Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.
Women 18 years or older diagnosed with epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer (hereafter referred to as OC).
Inclusion Criteria:
- Women with a pathologic diagnosis of OC.
- Able to provide informed consent.
- Patients receiving treatment at Mayo Clinic Rochester.
Exclusion Criteria:
- Borderline tumor or non-epithelial histology (germ cell tumor, carcinosarcoma, etc.).
- Other malignancy within the past five years, other than non-melanoma skin cancers that have been completely resected or cervical carcinoma in situ.
- Already received systemic chemotherapy for OC prior to study entry.
Participating Mayo Clinic locations
Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.
| Mayo Clinic Location |
Status |
Contact |
Rochester, Minn.
Mayo Clinic principal investigator Matthew Block, M.D., Ph.D. |
Open for enrollment |
Contact information:
Cancer Center Clinical Trials Referral Office
(855) 776-0015
|
More information
Publications
Publications are currently not available